ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: The dysregulation of cell cycle and DNA repair, ABC transporters, and JAK-STAT signaling pathway after treatment with nilotinib are interesting, since previous studies highlighted the role of these pathways in CML.